scispace - formally typeset
C

Carol L. Szumlanski

Researcher at Mayo Clinic

Publications -  36
Citations -  5494

Carol L. Szumlanski is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Thiopurine methyltransferase & Thiopurine S-Methyltransferase. The author has an hindex of 27, co-authored 36 publications receiving 5358 citations. Previous affiliations of Carol L. Szumlanski include Royal Hallamshire Hospital & Dartmouth College.

Papers
More filters
Journal ArticleDOI

Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders.

TL;DR: The identification of a gentic marker associated with significant alterations in enzyme activity will facilitate the analysis of a possible role for the COMT gene in neuropsychiatric conditions in which abnormalities in catecholamine neurotransmission are believed to occur.
Journal ArticleDOI

Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase.

TL;DR: Experimental strategies used to study methylation pharmacogenetics illustrate the rapid evolution of biochemical, pharmacologic, molecular, and genomic approaches that have been used to determine the role of inheritance in variation in drug metabolism, effect, and toxicity.
Journal ArticleDOI

Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms

TL;DR: Characterization of variant alleles for low TPMT enzyme activity will help make it possible to assess the potential clinical utility of deoxyribonucleic acid‐based diagnostic tests for determining T PMT genotype.
Journal ArticleDOI

Thiopurine Methyltransferase Pharmacogenetics: Human Gene Cloning and Characterization of a Common Polymorphism

TL;DR: Molecular cloning and structural characterization of the TPMT gene as well as elucidation of the molecular basis for a common T PMT genetic polymorphism will help make it possible to develop DNA-based diagnostic tests for the polymorphism and to determine the mechanism by which it results in decreased expression of this important drug-metabolizing enzyme.
Journal ArticleDOI

Immunosuppressive CD14+HLA-DRlow/− Monocytes in Prostate Cancer

TL;DR: To determine if the levels of circulating myeloid‐derived suppressor cells increase with progression of prostate cancer (PCa); to determine if such cells could contribute to the relative inefficiency of PCa immunotherapy.